Regeneron Pharmaceuticals, Inc. (REGN)
Regeneron is a science-led company that discovers and develops medicines to treat serious diseases, from eye conditions to inflammatory illnesses.
Is Regeneron Pharmaceuticals, Inc. a good stock for a UK beginner?
The honest version: Regeneron is a science-led company that discovers and develops medicines to treat serious diseases, from eye conditions to inflammatory illnesses.
Over about 2 years to 2026-07-31. This is the share price only - reinvesting the dividends would add to it. And it's the USD return - as a UK investor your actual £ return also moves with the exchange rate. Past performance is not a guide to the future, and it could just as easily have fallen.
Based on beta - how much the price swings versus the whole market. Bumpier isn't bad; it just means a rougher ride, which matters more the sooner you might need the money.
Prices move on results, news and the mood of the whole market - no single headline explains a day, and a quiet week is usually just noise, not a signal.
Breakthrough discoveries lead to major new revenue streams.
Failure to innovate or loss of key patent exclusivity.
What does Regeneron Pharmaceuticals, Inc. do?
Regeneron focuses on finding new ways to treat complex health issues, often using its own unique technology to create targeted therapies. Its income comes from selling these specialised medicines to hospitals and pharmacies globally. Its future growth really comes down to how well their pipeline of new drugs performs in clinical trials.
On our factor screen it looks strongest on momentum and quality, and weakest on growth.
- ✓Pays a dividend - about 0.5% a year
- ✓Growing - revenue up about 19% over the year
- ✓Very profitable - turns about 30% of sales into profit
- ✓Low debt - a sturdier balance sheet
- Momentum screens high (71/100)
- Strong profit margins indicate an efficient business model.
- Low beta suggests the stock is less volatile than the broader market.
- Double-digit revenue growth shows healthy demand for their products.
- Heavy reliance on the success of a few key drugs.
- Strict government regulations can impact pricing and profitability.
- The high cost of research and development means money can be spent with no guarantee of a successful medicine.
What do Regeneron Pharmaceuticals, Inc.'s numbers mean?
How much money does Regeneron Pharmaceuticals, Inc. make?
Revenue and profit by quarter, and how much of each sale turns into profit.
Does Regeneron Pharmaceuticals, Inc. pay a dividend?
Yes - Regeneron Pharmaceuticals, Inc. currently pays a dividend of about 0.5% a year (the yearly payout as a share of the price). A dividend is a slice of profit handed to shareholders; the yield moves as the price moves, and a company can cut or stop it.
When does Regeneron Pharmaceuticals, Inc. report earnings, and how did recent quarters go?
Regeneron Pharmaceuticals, Inc. is next scheduled to report on about 2026-10-28 - dates can move, and we don't predict results; this just tells you when to look.
Each quarter a company reports its results against what analysts expected. ‘Beating’ or ‘missing’ is about that expectation, not whether the business is doing well in absolute terms.
| Reported | Expected EPS: The earnings per share analysts expected for the quarter - the average of their forecasts. 'Beating' or 'missing' is measured against this number. | Actual EPS | vs expected |
|---|---|---|---|
| 2026-07-30 | $10.21 | $14.29 | Beat +40% |
| 2026-04-29 | $8.90 | $9.47 | Beat +6% |
| 2026-01-30 | $10.75 | $11.44 | Beat +6% |
| 2025-10-28 | $9.64 | $11.83 | Beat +23% |
| 2025-08-01 | $8.44 | $12.89 | Beat +53% |
| 2025-04-29 | $8.48 | $8.22 | Missed -3% |
Across the last 6 quarters here, Regeneron Pharmaceuticals, Inc. came in ahead of what analysts expected 5 times. One quarter is noise, not a trend.
See who else reports over the next two weeks →
Reported vs expected earnings per share (EPS) from published results; the expectation is the analyst consensus, not our view. Report dates are estimates that can move.
More in Healthcare
Eli Lilly
West Pharmaceutical Services, Inc.
Incyte Corporation
The Cigna Group
Zimmer Biomet Holdings, Inc.
Moderna, Inc.
Gilead Sciences, Inc.
Agilent Technologies, Inc.What are the scenarios for Regeneron Pharmaceuticals, Inc.?
An illustrative range for the year ahead, with the assumption behind each case — not a prediction or a price target.
What are the pros and cons of Regeneron Pharmaceuticals, Inc.?
How many points the write-up makes each way — a balance check, not a score or verdict.
- Strong profit margins indicate an efficient business model.
- Low beta suggests the stock is less volatile than the broader market.
- Double-digit revenue growth shows healthy demand for their products.
- Earnings growth has dipped recently, which can be a concern for investors.
- The pharmaceutical industry is notoriously expensive and slow to develop new products.
- Small dividend yield may not appeal to those looking for regular income.
- Heavy reliance on the success of a few key drugs.
- Strict government regulations can impact pricing and profitability.
- The high cost of research and development means money can be spent with no guarantee of a successful medicine.
The write-up's own warning lights — if these start happening, the case above changes.
- A major, unexpected failure in a late-stage clinical trial.
- Significant changes to government healthcare spending policies that limit drug prices.
Built from public filings & market prices, checked for an education-only tone, and never a price target. How we make these →
This plain-English summary was auto-generated on 2026-08-01 from public data and checked for an education-only, no-advice tone (the figures above carry their own, usually fresher, 'as of' date). It's information, never a recommendation.